Author

Aurora Vigato

Université Libre de Bruxelles

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Benjamin BeckiD· 1 shared Diego Japon-RuiziD· 1 shared Fabiana MoresiiD· 1 shared Marta Ávalos-MorenoiD· 1 shared Xavier BisteauiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

5 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Benjamin BeckORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cisplatin-Induced Plasticity Drives Cross-Resistance to CDK4/6 Inhibitors and Reveals Targetable Vulnerabilities Through HDAC Inhibition in Esophageal Squamous Cell Carcinoma.

Marta Ávalos-Moreno, Aurora Vigato, Fabiana Moresi, Diego Japon-Ruiz, Benjamin Beck, Xavier Bisteau

This study shows cisplatin resistance in ESCC leads to an immune-evasive, drug-tolerant state that confers cross-resistance to CDK4/6 inhibitors, which can be reversed by HDAC inhibitors.

bioRxiv · Jul 17, 2026 · PreprintCancer Biology